Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$52.01 USD

52.01
839,272

+0.71 (1.38%)

Updated Jul 3, 2024 01:00 PM ET

After-Market: $52.03 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU

Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 14.49% and 2.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.